Amicus, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a $14.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum has given his Buy rating due to a combination of factors including Amicus’s strong financial performance in the third quarter of 2025. The company reported robust sales for both Galafold and pom/opf, reaching their highest demand levels to date. This performance aligns with both the firm’s and market expectations, reinforcing confidence in the company’s financial health.
Amicus has also maintained its full-year sales growth guidance for pom/opf, projecting a significant increase of 50-65% at constant exchange rates. Additionally, the company is on track with its pivotal study enrollment for DMX-200, which could potentially expedite its market entry. These strategic and operational achievements underpin the positive outlook and justify the Buy rating.
In another report released on October 22, Bank of America Securities also reiterated a Buy rating on the stock with a $14.00 price target.